Amylin, Alkermes announce availability of Bydureon in US
Amylin Pharmaceuticals and Alkermes have announced the availability of Bydureon (exenatide extended-release for injectable suspension) by prescription in the US pharmacies.
Bydureon, once-weekly treatment for type 2 diabetes, was approved by FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The approval was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with Bydureon resulted in improvements in glycemic control in a once-weekly dose.
Bydureon is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous (under the skin) injection, the companies said.
Related Insight
Suppliers Directory
Geodis Wilson - Global Pharmaceutical Freight Management Services
Geodis Wilson is a leading global freight management company. They manage sea and air cargo across five continents, making supply chains transparent and flexible to handle.
Drug Research > Drug Delivery > Suppliers
Tecnosoft - Monitoring Systems for Temperature, Humidity and Pressure
Tecnosoft is a system development company working for big third party companies while also steering its own product line with its own brand. We have a lot of experience and a great know-how in the medical and geotechnical industry, having developed and produced data acquisition systems for both markets, in Italy and all around the world, for different leading companies.
Drug Research > Drug Delivery > Suppliers
Hapa - Late Stage Customisation and On Demand Printing Technologies
Hapa is the world leader in late stage customisation and on demand printing technologies for the pharmaceutical sector, delivering fast, accurate and value-creating packaging solutions.
Drug Research > Drug Delivery > Suppliers
Trinean - UV-VIS Spectral Analysis of DNA/RNA, Protein or Small Compounds
Trinean develops and produces a new approach for high throughput full scan UV-VIS spectral analysis of microliter droplets of DNA/RNA, protein or small compounds.
Drug Research > Drug Delivery > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Delivery Intelligence
Points to Consider in Choosing a CRO
Published by Multipharma
Drug Research > Drug Delivery > White Papers
Crossject - No Need for Needles
Published by Crossject
Drug Research > Drug Delivery > White Papers
R&D Laboratory Micronisation Equipment
Published by FPS Food and Pharma Systems Srl
Drug Research > Drug Delivery > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.